Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P555: Systematic review of interventions for chronic abdominal pain management in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Norton C.1, Czuber-Dochan W.2, Artom M.2, Sweeney L.*2, Hart A.3

1King's College, Faculty of Nursing and Midwifery, London, United Kingdom 2King's College London, Faculty of Nursing and Midwifery, London, United Kingdom 3St Marks Hospital, Gastroentrology, London, United Kingdom

P556: Female Crohn's disease patients and ulcerative colitis patients on biologic therapy are most disabledECCO '17 Barcelona
Year: 2017
Authors:

Spizzo P.

St Vincent's Hospital Melbourne, Victoria, Australia

P557: Utility of “trough levels” adalimumab determination in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters through population pharmacokinetic modelECCO '17 Barcelona
Year: 2017
Authors:

Juan G.*1, Alvariño A.2, Mora M.3, Oltra L.3, Maroto N.3, Ferrer I.3, Hinojosa E.3, Hinojosa M.D.3, Hinojosa J.3

1Hospital de Manises, Department of Pharmacy, Manises, Spain 2Hospital de Manises, Department of Labratory, Manises, Spain 3Hospital de Manises, IBD Unit, Manises, Spain

P558: The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Rubin D.T.*1, Panés J.2, Lindsay J.O.3, Vermeire S.4, Yarlas A.5, Bayliss M.5, Cappelleri J.C.6, Maher S.5, Bushmakin A.G.6, Chen L.A.7, Manuchehri A.8, Healey P.6

1The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, United States 2Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain 3Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom 4Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium 5Optum, Lincoln, RI, United States 6Pfizer Inc, Groton, CT, United States 7New York University School of Medicine, New York, NY, United States 8Pfizer Ltd, Tadworth, United Kingdom

P559: Treatment goals in IBD: a perspective from patients and their partnersECCO '17 Barcelona
Year: 2017
Authors:

Peek-Kuijt N., Aantjes M., Verwey M., van der Meulen-de Jong A., Maljaars P.

Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands

P560: Trough levels at induction: impact on long term response when re-initiating infliximabECCO '17 Barcelona
Year: 2017
Authors:

Liefferinckx C.*1, Minsart C.2, Toubeau J.-F.3, Cremer A.4, Amininejad L.4, Quertinmont E.2, Devière J.4, Gils A.5, Van Gossum A.4, Franchimont D.4

1Université libre de bruxelles, Laboratory of Experimental Gastroenterology, Brussels, Belgium 2Université libre de Bruxelles, Laboratory of Experimental Gastroenterology, Brussels, Belgium 3Université de Mons, Department of Electrical Engineering, Mons, Belgium 4Erasme Hospital, Gastro-enterology, Brussels, Belgium 5KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

P561: Can we predict adherence to treatment in IBD patients?ECCO '17 Barcelona
Year: 2017
Authors:

Naftali T.*1, Ein Dor A.2,3, Ruhimovich N.4, Shitrit A.B.5, Sklerovsky Benjaminov F.2,4, Matalon S.2,3, Shirin H.3,6, Konikoff F.M.1,2, Broide E.3,6

1Meir medical center, Gastroenterology, Kfar Saba, Israel 2Tel Aviv university Sackler school of medicin, internal medicine, Tel Aviv, Israel 3Assaf Harofeh Medical Center, The Kamila Gonczarowski institute of Gastroenterology Assaf Harofeh Medical Center, Zerifin, Israel 4Meir Medical Center, Department of Gastroenterology & Hepatology, Kfar Saba, Israel 5Shaare Zedek Medical Center, Department of Gastroenterology and Digestive Diseases, Jerusalem, Israel 6Tel Aviv university Sackler school of medicin, internal medicine, Tel aviv, Israel

P562: Real-life infliximab trough levels among inflammatory bowel disease patients on maintenance therapy: should we redefine therapeutic range based on inflammatory load?ECCO '17 Barcelona
Year: 2017
Authors:

Lobaton T.*1, Cañete F.1, Teniente A.2, Cabre E.1,3, Mañosa M.1, Martínez E.2, Domènech E.1,3

1University Hospital Germans Trias i Pujol, Gastroenterology, Badalona (Barcelona), Spain 2University Hospital Germans Trias i Pujol, Immunology, Badalona (Barcelona), Spain 3CIBER, Badalona (Barcelona), Spain

P563: Psychotherapy experience and demand for it and their association in inflammatory bowel disease – results from an internet-based surveyECCO '17 Barcelona
Year: 2017
Authors:

Klag T.*1, Mazurak N.2, Fantasia L.1, Schwille-Kiuntke J.2, Kirschniak A.3, Goetz M.1, Malek N.1, Enck P.2, Wehkamp J.1

1University Hospital Tuebingen, Internal Medicine I, Tuebingen, Germany 2University Hospital Tuebingen, Internal Medicine VI, Tuebingen, Germany 3University Hospital Tuebingen, General Surgery, Tuebingen, Germany

P564: Low-dose azathioprine improves long-term efficacy of infliximab maintenance treatment in Japanese patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Nasuno M.*1, Motoya S.1, Sugiyama K.1, Miyakawa M.1, Tanaka H.1, Iida T.2, Onodera K.2, Nakase H.2

1Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan 2Sapporo Medical University, School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan

P565: Assessments of clinical efficacy and mucosal healing in ulcerative colitis patients undergoing granulomonocytapheresis at different treatment frequenciesECCO '17 Barcelona
Year: 2017
Authors:

Ohmori T., Ohmori S.

Ohmori Toshihide GastroIntestinal Clinic, Ageo, Japan

P566: Frequency and type of drug-related side effects necessitating drug cessation in the Swiss inflammatory bowel disease cohortECCO '17 Barcelona
Year: 2017
Authors:

Godat S.*1, Fournier N.2, Safroneeva E.3, Marot A.1, Deltenre P.1, Hahnloser D.4, Straumann A.5, Vavricka S.6, Biedermann L.7, Rogler G.8, Schoepfer A.1

1CHUV - Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology and Hepatology, Lausanne, Switzerland 2University of Lausanne, Institute of Social and Preventive Medicine, Lausanne, Switzerland 3University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland 4Centre Hospitalier Universitaire Vaudois CHUV, Department of Visceral Surgery, Lausanne, Switzerland 5Swiss EoE Center, Praxis Roemerhof, Olten, Switzerland 6Stadtspital Triemli, Department of Gastroenterology and Hepatology, Zurich, Switzerland 7University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland 8University Hospital Zürich, Department of Gastroenterology and Hepatology, Zurich, Switzerland

P567: Cross-sectional study of the low serum concentrations of testosterone in IBD and the influence on disease activityECCO '17 Barcelona
Year: 2017
Authors:

Hlavaty T., Krajcovicova A., Kollerova J., Koller T., Leskova Z., Sturdik I., Payer J.

Comenius University, Faculty of Medicine and University Hospital Bratislava, 5th Department of Internal Medicine, Bratislava, Slovakia

P568: Does infliximab therapy increase incidence of tuberculosis in patients with inflammatory bowel disease in an endemic area: a nationwide study from ChinaECCO '17 Barcelona
Year: 2017
Authors:

Ye L., Liu J., Lin Z., Cao Q.

Inflammatory Bowel Disease Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

P569: Sequential rescue treatments in steroid refractory ulcerative colitis: two-year follow-upECCO '17 Barcelona
Year: 2017
Authors:

Protic M.*1, Seibold F.2,3, Manser C.4, Frei P.5, Mottet C.6, Juillerat P.7, Knezevic T.1, Rogler G.4, Beglinger C.8, Schoepfer A.9, Vavricka S.10

1University Hospital Zvezdara, Department of Gastroenterology, Belgrade, Serbia 2Cantonal Hospital Fribourg, Division of Gastroenterology and Hepatology, Fribourg, Switzerland 3Lindenhofspital, Crohn Colitis Center, Bern, Switzerland 4University Hospital Zurich, Department of Gastroenterology, Zurich, Switzerland 5See Spital, Department of Gastroenterology, Zürich, Switzerland 6Hospital Neuchâtel, Department of Gastroenterology, Neuchâtel, Switzerland 7University Hospital Bern, Gastroenterology and Hepatology, Bern, Switzerland 8University Hospital Basel, Division of Gastroenterology & Hepatology, Basel, Switzerland 9Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology, Lausanne, Switzerland 10Stadtspital Triemli, Department of Gastroenterology, Zürich, Switzerland

P570: Current status of the effectiveness of infliximab in patients with ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Yokoyama K.*1, Kawagishi K.1, Kobayashi K.2, Koizumi W.1

1Kitasato University School of Medicine, Department of Gastroenterology, Sagamihara, Japan 2Kitasato University School of Medicine, Research and Development Center for New Medical Frontiers, Sagamihara, Japan

P571: Can Crohn's colits be cured by surgery?ECCO '17 Barcelona
Year: 2017
Authors:

Calafiore A., Sgambato D., Rizzello F., Calabrese C., Poggioli G., Laureti S., Calandrini L., Mazza M., Praticò C., Salice M., Campieri M., Gionchetti P.

University of Bologna, Dept of Clinical and Surgical Sciences - IBD Unit, Bologna, Italy

P572: Medical therapies for stricturing Crohn's disease: efficacy and cross-sectional imaging predictors of therapeutic failureECCO '17 Barcelona
Year: 2017
Authors:

Campos C.1, Perrey A.2, Lambert C.3, Pereira B.3, Goutte M.1,4, Goutorbe F.1,5, Dubois A.6, Reymond M.1, Allimant C.1, Dapoigny M.1, Bommelaer G.1,4, Hordonneau C.2, Buisson A.*1,4

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France 2University Hospital Estaing, Radiology Department, Clermont-Ferrand, France 3University Hospital, Biostatistics Unit, DRCI, Clermont-Ferrand, France 4UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France 5Hospital of Bayonne, Gastroenterology Department, Bayonne, France 6CHU Estaing, Department of Digestive surgery, Clermont-Ferrand, France

P573: Impact of the duration of combination therapy on clinical and pharmacological efficacy of infliximab in inflammatory bowel diseasesECCO '17 Barcelona
Year: 2017
Authors:

Vernet C., Roblin X., Williet N.

CHU, LOIRE, Saint Etienne, France

P574: Limitations and difficulties in using anti-TNF-alpha agents in inflammatory bowel disease. A survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD)ECCO '17 Barcelona
Year: 2017
Authors:

Saibeni S.*1, Bezzio C.1, Armuzzi A.2, Bossa F.3, Calabrese E.4, Caprioli F.5, Daperno M.6, Mocciaro F.7, Orlando A.8, Papi C.9, Rispo A.10, Rizzello F.11 IG-IBD

1ASST Rhodense, Gastroenterology Unit, Rho, Italy 2Policlinico Gemelli, Rome, Italy 3Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy 4Policlinico Tor Vergata, Rome, Italy 5University of Milan, Milan, Italy 6Ospedale Mauriziano, Torino, Italy 7Ospedale Arnas Civico, Palermo, Italy 8Ospedale Cervello, Palermo, Italy 9Ospedale San Filippo Neri, Rome, Italy 10Policlinico Federico II, Naples, Italy 11University of Bologna, Bologna, Italy